Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer AG  is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

Explainer: What are the obstacles to Bayer settling Roundup lawsuits?

Elanco Animal Health Inc

Bayer (BAYRY) inks deal with Elanco to divest its animal health business for $7.6 billion.

Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco

On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

Bayer Sells Animal Health Division to Elanco: Now What?

Elanco Animal Health Inc (NYSE: ELAN) shares were trading lower Tuesday after the company announced it would acquire Bayer AG (OTC: BAYRY)'s animal health business for $5.32 billion in cash and $2.28 billion in Elanco shares.

Elanco To Acquire Bayer's Animal Health Business For $7.6B

Elanco Animal Health  agreed to buy Bayer's  veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest animal health business and expanding Elanco's reach online.

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health  said on Tuesday it would buy Bayer's  veterinary drugs unit in a cash and stock deal valued at $7.6 billion, creating the second largest animal health business and expanding Elanco's reach in the pet e-commerce space.

Elanco to buy Bayer's animal health unit for $7.6 billion

Elanco Animal Health ELAN, +1.53% said it's buying Bayer's BAYN, -0.77% animal health business for $7.6 billion.

Elanco buying Bayer's animal health business for $7.6 billion

Bayer AG has not proposed paying $8 billion to settle all U.S. claims related to the Roundup herbicide, mediator Ken Feinberg said in an email on Friday.

Bayer has not proposed paying $8 billion to settle U.S. Roundup claims: mediator

The stock was on track for its best single-day gain in a decade as traders said the settlement report from Bloomberg could relieve pressure on Bayer shares.

Bayer soars on report of proposed $8 billion Roundup settlement

Biotech M&A has been on a roll this year, with companies striking up both mid- and large-sized deals.

Bayer To Buyout Stem Cell Therapy Company BlueRock For Up To $600M

Bayer AG BAYRY, +6.54% is acquiring BlueRock Therapeutics, a privately-held U.S.-based biotech developing engineered cell therapies in the areas of neurology, cardiology and immunology, the companies announced Thursday.

Bayer to acquire biotech BlueRock Therapeutics

German drugmaker Bayer  is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.

Bayer buys BlueRock in $600 million bet on stem cell therapies

Germany's Bayer  said the next U.S. lawsuit scheduled to be heard over claims that its glyphosate-based weedkiller Roundup, causes cancer would likely be postponed.

Bayer says next glyphosate lawsuit likely to be postponed

German chemical groups Bayer  and Lanxess  have agreed to sell integrated chemical site operator Currenta to Macquarie Infrastructure and Real Assets (MIRA)  for an enterprise value of 3.5 billion euros ($3.9 billion).

Lanxess, Bayer sell chemical park operator to Macquarie for $3.9 billion

A Bayer executive on Thursday said the company was closely watching the plant-based meat market which has seen booming demand in recent years, adding that Bayer could potentially enter the market as an alternative protein source provider.

Bayer sees potential future business in plant-based meat market

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q2 2019 Results - Earnings Call Transcript

Bayer on Tuesday said it would consider settling with U.S. plaintiffs suing over the German group's Roundup herbicide only on reasonable terms, and if such a move wraps up all cases.

Bayer sees glyphosate settlement only if financially reasonable

Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.

Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y

Germany's Bayer became the latest agricultural supplies company to be affected by flooded farms in the United States and by trade disputes, saying its full-year earnings target has become harder to reach.

Bayer says 2019 profit goal becoming a stretch

Germany's Bayer AG , which completed the takeover of U.S.-based Monsanto last year, has been dealt a legal blow in Brazil as more farmers joined a lawsuit challenging the protection of a key soy seed patent.

Germany's Bayer dealt new legal blow as more Brazil farmers challenge soy patent

A California judge on Thursday reduced a $2 billion jury verdict, slashing the award for a couple who blamed Bayer AG's glyphosate-based weed killer Roundup for their cancer to $86.7 million.

In Roundup case, U.S. judge cuts $2 billion verdict against Bayer to $86 million

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Bayer (BAYRY) Stock?

AbbVie

Merck

Roche Holding AG

Sanofi

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bayer (BAYRY) Upgraded to Buy: What Does It Mean for the Stock?

Bayer AG , facing an upcoming trial in St. Louis over allegations that its Roundup weed killer causes cancer, has recruited Missouri-based expert witnesses to make its case in a place where it has century-old roots but where juries often hit companies with huge damages.

News for Bayer AG Stock (BAYRY)